Payment overview · 2025
General Payments
$581.20
31 reported records · 14 companies
Healthcare provider profile · identity verified
Keri Jane Mullins, APRN-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OBLONG, IL · NPI 1710143367
Verified facts
What the public records show
CMS Open Payments records show Keri Jane Mullins, APRN-BC received $581.20 in general payments during 2025 across 31 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $107.50 | 18.5% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $83.40 | 14.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.86 | 12.9% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.23 | 10.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.69 | 8.4% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $47.80 | 8.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.55 | 5.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.61 | 4.4% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $20.35 | 3.5% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $19.22 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.22 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.86 | 2.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.53 | 2.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $14.38 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $581.20 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $107.50 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $74.86 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $60.23 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $51.16 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $48.69 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $31.69 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 472 | 85 |
| Losartan Potassium | Losartan Potassium | 368 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 38 |
| Lisinopril | Lisinopril | 243 | 46 |
| Metformin Hcl Er | Metformin Hcl | 213 | 41 |
| Montelukast Sodium | Montelukast Sodium | 198 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 25 |
| Gabapentin | Gabapentin | 162 | 24 |
| Omeprazole | Omeprazole | 160 | 27 |
| Sertraline Hcl | Sertraline Hcl | 152 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 30 |
| Famotidine | Famotidine | 132 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 17 |
| Ezetimibe | Ezetimibe | 110 | 20 |
| Celecoxib | Celecoxib | 93 | 28 |
| Alendronate Sodium | Alendronate Sodium | 85 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 19 |
| Furosemide | Furosemide | 71 | 17 |
| Meloxicam | Meloxicam | 70 | 21 |
| Jardiance | Empagliflozin | 66 | 16 |
| Tramadol Hcl | Tramadol Hcl | 66 | 14 |
| Allopurinol | Allopurinol | 61 | 11 |
| Metformin Hcl | Metformin Hcl | 60 | 17 |
| Eliquis | Apixaban | 59 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | suppressed |
| Simvastatin | Simvastatin | 58 | suppressed |
| Lovastatin | Lovastatin | 56 | suppressed |
| Potassium Chloride | Potassium Chloride | 52 | 11 |
| Glipizide Er | Glipizide | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 36 | 32 |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 11 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Minoxidil | Minoxidil | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Prednisone | Prednisone | 17 | 16 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $581.20 · 31 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AREXVY, ARISTADA, Auvelity, Azstarys, CAPLYTA, Cologuard Collection Kit, FANAPT, INGREZZA, INVEGA SUSTENNA, LYBALVI, MOUNJARO, NUEDEXTA, PENMENVY, REXULTI, SHINGRIX, SPRAVATO, UZEDY, VRAYLAR, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error